Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.

@article{Subklewe2007DendriticCM,
  title={Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.},
  author={Marion Subklewe and Kathrin Sebelin-Wulf and Carola Beier and Andreas Lietz and Stephan Mathas and Bernd Doerken and Antonio Pezzutto},
  journal={Human immunology},
  year={2007},
  volume={68 3},
  pages={147-55}
}
The proteasome inhibitor bortezomib has been used successfully in the treatment of non-Hodgkin lymphomas in humans, and in the treatment of graft versus host disease (GVHD) and autoimmune diseases in animal models. The mechanism of growth inhibition and immunosuppression is only partly understood. Here, we have evaluated the differential effect of bortezomib on human monocyte derived immature and mature dendritic cells (DCs) as the maturation stage of DCs determines their function. We found… CONTINUE READING
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…